Chu Rebecca
NYU Winthrop, Mineola, New York.
Pediatr Allergy Immunol Pulmonol. 2019 Sep 1;32(3):128-130. doi: 10.1089/ped.2019.1066. Epub 2019 Sep 17.
Nasal polyps are a concern for both adults and children. The treatment of nasal polyps typically is glucocorticoids, both topically and systemically administered. However, patients often experience refractory nasal polyps. A proposed reason for unsatisfactory treatment for the reoccurrence of nasal polyps is because of the drug delivery options through the nose that requires patients to coordinate actuation, head placement, and administration. In addition, many of these delivery systems have shown poor delivery efficiency due to medication depositing into the lungs. To combat these difficulties, Optinose has created an exhalation delivery system that could be used for both liquid and powered medications. Xhance (fluticasone propionate), which uses this new delivery system, is currently approved for the treatment of nasal polyps in adults. It has shown promising results in adults and is currently undergoing evaluation in pediatric patients.
鼻息肉是成人和儿童都关心的问题。鼻息肉的治疗通常使用糖皮质激素，包括局部和全身给药。然而，患者经常会出现难治性鼻息肉。对于鼻息肉复发治疗效果不理想的一个原因是通过鼻腔给药时，患者需要协调启动、头部位置和给药操作。此外，由于药物沉积到肺部，许多这些给药系统的给药效率都很低。为了克服这些困难，Optinose公司开发了一种呼气给药系统，可用于液体和粉末状药物。使用这种新给药系统的Xhance（丙酸氟替卡松）目前已被批准用于治疗成人鼻息肉。它在成人中已显示出有希望的结果，目前正在儿科患者中进行评估。
